Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Accendra Health, Inc.NYSE: ACH
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $3.09M fell 55.4% year over year, ahead of the -78.3% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -15.0% a year.
Context
- Stock-based compensation amounted to 0.5% of revenue in FY2025, up 0.2 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -55.4% holds above the trailing-twelve-month pace of -78.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.87M USD
- Year-over-year change
- -52.0%
- 4-year CAGR
- -15.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.87M | -52.0% |
| FY2024 | 2024-12-31 | 26.84M | +15.6% |
| FY2023 | 2023-12-31 | 23.22M | +10.6% |
| FY2022 | 2022-12-31 | 20.99M | -16.1% |
| FY2021 | 2021-12-31 | 25.02M | — |
Stock-Based Compensation vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -78.3% is the lowest of 11, against a peer median of -16.3%.
- Stock-based compensation amounts to 0.2% of revenue for ACH, versus a peer median of 17.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.74M USD | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $21.03M USD | +1.0% | +44.8% | — | |
| LTM Mar 2026 | $16.09M USD | -33.3% | -16.9% | 13.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $13M USD | +43.2% | +66.3% | 126.0% |
| LTM Mar 2026 | $12.05M USD | -2.1% | -6.3% | 144.0% | |
| LTM Mar 2026 | $11.67M USD | -30.6% | +0.2% | 14.7% | |
| LTM Mar 2026 | $11.51M USD | +11.1% | +41.7% | 19.5% | |
| LTM Mar 2026 | $9.12M USD | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | $5.84M USD | -78.3% | -15.0% | 0.2% | |
| LTM Mar 2026 | CA$4.6M CAD | +209.3% | -38.3% | 1.5% | |
| LTM Apr 2026 | CA$1.86M CAD | -54.1% | -21.4% | 0.3% | |
| Peer median (excluding ACH) | — | -16.3% | -11.6% | 17.1% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (102.68M) |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| Deferred Income Tax | (29.74M) | (26.36M) | (23.65M) | (26.12M) | (17.89M) |
| Stock-Based Compensation | 25.02M | 20.99M | 23.22M | 26.84M | 12.87M |
| Change in Working Capital | (261.4M) | 89.77M | 522.29M | (25.44M) | 65.21M |
| Accounts Receivables | (2.2M) | 1.1M | 166.58M | (94.55M) | 122.36M |
| Inventory | (263.44M) | 166.56M | 224.34M | (26.23M) | (6.85M) |
| Accounts Payables | 3.55M | 13.65M | 31M | 65.19M | 6.48M |
| Other Working Capital | 692K | (91.54M) | 100.37M | 30.15M | (56.78M) |
| Other Non-Cash Items | 78.09M | (10.45M) | (27.22M) | 284.12M | (273.83M) |
| Operating Cash Flow | 124.18M | 325.01M | 740.71M | 161.5M | (101.79M) |
| Capital Expenditures | (49.69M) | (166.58M) | (207.89M) | (228.16M) | (201.33M) |
| Acquisitions (Net) | (43.37M) | (1.68B) | 0 | 0 | 324.26M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 39.43M | 46.71M | 53.62M | 94.33M | 11.12M |
| Investing Cash Flow | (53.63M) | (1.8B) | (137.25M) | (116.53M) | 144.42M |
| Debt Repayment | (95.35M) | 1.58B | (416.69M) | (244.2M) | 203.5M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (10.18M) |
| Dividends Paid | (731K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (33.4M) | (85.4M) | (637K) | (23.41M) | (5.24M) |
| Financing Cash Flow | (129.48M) | 1.5B | (417.33M) | (267.6M) | 188.08M |
| Effect of Forex Changes | (3.54M) | (3.49M) | 613K | (901K) | 1.9M |
| Net Change in Cash | (62.47M) | 14.15M | 186.74M | (223.54M) | 232.61M |
| Free Cash Flow | 74.49M | 158.42M | 532.82M | (66.67M) | (303.12M) |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.